VERICEL CORPORATION Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
VERICEL CORPORATION (VCEL) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $2.31 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-02-26
- VERICEL CORPORATION effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $2.31M.
- VERICEL CORPORATION effective income tax rate reconciliation, tax credit, research, amount for fiscal 2016 was $0.00.
- VERICEL CORPORATION effective income tax rate reconciliation, tax credit, research, amount for fiscal 2015 was $0.00.
- VERICEL CORPORATION effective income tax rate reconciliation, tax credit, research, amount for fiscal 2014 was -$1.60M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.31M 10-K · filed 2026-02-26 | |
| 2016-12-31 | $0.00 10-K · filed 2017-03-13 | |
| 2015-12-31 | $0.00 10-K · filed 2017-03-13 | |
| 2014-12-31 | -$1.60M 10-K · filed 2017-03-13 | $1.60M 10-K · filed 2015-03-25 |
| 2013-12-31 | $0.00 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |